Evidence map›Paper›PMID 37797071›Full record

SynthesisPloS one2023

Identifying patients with multidrug-resistant tuberculosis who may benefit from shorter durations of treatment.

Nicholas Winters, Mireille E Schnitzer, Jonathon R Campbell, Susannah Ripley, Carla Winston, Rada Savic, Nafees Ahmad, Gregory Bisson, Keertan Dheda, Ali Esmail and 7 more

Open access · goldAbstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 82% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 12 institutions in 9 countries.

Nicholas WintersDepartment of Epidemiology, Biostatistics and Occupational Health, McGill University, Canada.ORCID 0000-0001-5391-4381
Mireille E SchnitzerDepartment of Epidemiology, Biostatistics and Occupational Health, McGill University, Canada.
Jonathon R CampbellDepartment of Medicine & Department of Global and Public Health, Faculty of Medicine and Health Sciences, McGill University, Montreal, Canada.
Susannah RipleyDepartment of Epidemiology, Biostatistics and Occupational Health, McGill University, Canada.
Carla WinstonUS Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
Rada SavicDepartment of Bioengineering and Therapeutic Sciences, University of California San Francisco Schools of Pharmacy and Medicine, San Francisco, California, United States of America.
Nafees AhmadFaculty of Pharmacy and Health Sciences, University of Baluchistan, Quetta, Pakistan.ORCID 0000-0002-6202-4345
Gregory BissonDepartment of Medicine and Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States of America.
Keertan DhedaCentre for Lung Infection and Immunity, Department of Medicine & UCT Lung Institute, University of Cape Town, Cape Town, South Africa.
Ali EsmailCentre for Lung Infection and Immunity, Department of Medicine & UCT Lung Institute, University of Cape Town, Cape Town, South Africa.
Medea GegiaGlobal Tuberculosis Program, World Health Organization, Geneva, Switzerland.
Ignacio MonederoTB-HIV Department, International Union against Tuberculosis and Lung Diseases, Paris, France.
Margareth Pretti DalcolmoCentro de Referência Helio Fraga, Fiocruz, Brazil.ORCID 0000-0002-6820-1082
Denise RodriguesInstituto Clemente Ferreira, Sao Paulo, Brazil.
Rupak SinglaNational Institute of Tuberculosis & Respiratory Diseases, New Delhi, India.
Jae-Joon YimDepartment of Internal Medicine, Division of Pulmonary and Critical Care Medicine, Seoul National University College of Medicine, Seoul, South Korea.
Dick MenziesDepartment of Epidemiology, Biostatistics and Occupational Health, McGill University, Canada.
McGill University · CAMcGill University Health Centre · CAUniversity of Cape Town · ZACenters for Disease Control and Prevention · USFundação Oswaldo Cruz · BRInternational Union Against Tuberculosis and Lung Disease · FRLRS Institute of Tuberculosis and Respiratory Diseases · INSeoul National University · KRUniversity of Balochistan · PKUniversity of California, San Francisco · USUniversity of Pennsylvania · USWorld Health Organization · CH

Funding

World Health Organization 001
6 · The paper itself

Abstract

objectiveStudying treatment duration for rifampicin-resistant and multidrug-resistant tuberculosis (MDR/RR-TB) using observational data is methodologically challenging. We aim to present a hypothesis generating approach to identify factors associated with shorter duration of treatment. STUDY DESIGN AND

settingWe conducted an individual patient data meta-analysis among MDR/RR-TB patients restricted to only those with successful treatment outcomes. Using multivariable linear regression, we estimated associations and their 95% confidence intervals (CI) between the outcome of individual deviation in treatment duration (in months) from the mean duration of their treatment site and patient characteristics, drug resistance, and treatments used.

resultsOverall, 6702 patients with successful treatment outcomes from 84 treatment sites were included. We found that factors commonly associated with poor treatment outcomes were also associated with longer treatment durations, relative to the site mean duration. Use of bedaquiline was associated with a 0.51 (95% CI: 0.15, 0.87) month decrease in duration of treatment, which was consistent across subgroups, while MDR/RR-TB with fluoroquinolone resistance was associated with 0.78 (95% CI: 0.36, 1.21) months increase.

conclusionWe describe a method to assess associations between clinical factors and treatment duration in observational studies of MDR/RR-TB patients, that may help identify patients who can benefit from shorter treatment.

Indexed as

Tuberculosis, Multidrug-ResistantAntitubercular AgentsDuration of TherapyFluoroquinolonesHumansRifampinTreatment OutcomeAntitubercular AgentsFluoroquinolonesRifampin

Identifiers

PMID37797071
PMCPMC10553332
OpenAlexW4387362542

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.